Newer vascular targets: Endosialin (review)

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 305-312

  Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Antiangiogenesis; Endosialin; Gene expression analysis; SAGE; Serial analysis of gene expression; TEM; Tumor endothelial markers; Vascular targets

Indexed keywords

ANGIOGENESIS INHIBITOR; CD164L1 PROTEIN, HUMAN; MEMBRANE PROTEIN; RNA; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PRENATAL DEVELOPMENT; REVIEW; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA;

EID: 34047249773     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Folkman J: Angiogenesis. Annu Rev Med 57: 1-18, 2006.
2. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.
3. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 13: 159-167, 2003.
4. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
5. Herbst RS, Onn A and Sandler A: Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256, 2005. (Pubitemid 46211349)
6. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S and Pruschy M: Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12: 3518-3524, 2006.
7. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC and Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249-8255, 2004. (Pubitemid 39491762)
8. Gasparini G, Longo R, Fanelli M and Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. J Clin Oncol 23: 1295-1311, 2005.
9. Teicher BA: Hypoxia, tumor endothelium and targets for therapy. In: Advances in Experimental Medicine & Biology. Okunieff P, Williams J and Chen Y (eds). Springer, New York NY, pp31-38, 2005.
10. Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW and Widschwendter M: Breast cancer DNA methylation profiles in cancer ccells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66: 29-33, 2006.
11. Weeraratna AT: Discovering causes and cures for cancer from gene expression analysis. Ageing Res Rev 4: 548-563, 2005. (Pubitemid 43293167)
12. Brentani RR, Carrari DM, Verjovski-Almeida S, Reis EM, Neves EJ, De Souza SJ, Carvalho AF, Brentani H and Reis LFL: Gene expression arrays in cancer research: methods and applications. Crit Rev Oncol/Hematol 54: 95-105, 2005.
13. Segal E, Friedman N, Kaminski N, Regev A and Koller D: From signatures to models: understanding cancer microarrays. Nat Genet 37: S38-S45, 2005.
14. Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GMJM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ and van Engeland M: Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 23: 7257-7264, 2005. (Pubitemid 46202340)
15. Espinosa E, Vara JAF, Redondo A, Sanchez JJ, Hardisson D, Zamora P, Pastrana F, Gomez CP, Martinez B, Suarez A, Calero F and Baron MG: Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 23: 7278-7285, 2005.
16. Chen C-N, Lin J-J, Chen J JW, Lee P-H, Yang C-Y, Kuo M-L, Chang K-J and Hsieh F-J: Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 23: 7286-7295, 2005.
17. Agnelli L, Bicciato S, Mattioli M, Fabri S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L and Neri A: Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23: 7296-7306, 2005.
18. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U and Dragani TA: Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23: 7307-7311, 2005.
19. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PRM, Macklis R, Tomlinson G, Huff V and Green DM: Loss of heterozygosity for chromosomes 1p and 16q Is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23: 7312-7321, 2005.
20. Bilke S, Chen Q-R, Westerman F, Schwab M, Catchpoole D and Khan J: Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 23: 7322-7331, 2005.
21. Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science 270: 484-487, 1995.
22. Porter D, Yao J and Polyak K: SAGE and related approaches for cancer target identification. Drug Discov Today 11: 110-118, 2006. (Pubitemid 43375961)
23. Beauchamp NJ, van Achterberg TAE, Engelse MA, Pannekoek H and De Vries CJM: Gene expression profiling of resting and activated vascular smooth muscle cells by serial analysis of gene expression and clustering analysis. Genomics 82: 288-299, 2003.
24. Polyak K and Riggins GJ: Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J Clin Oncol 19: 2948-2958, 2001.
25. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao X, St. Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan R-V, Lucey B, Carson-Walter EB, Laterra J and Walter KA: Vascular gene expression in non-neoplastic and malignant brain. Am J Pathol 165: 601-608, 2004. (Pubitemid 38971389)
26. Parker BS, Argani P, Cook BP, Liangfen H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St. Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S and Madden SL: Alerations in vascular gene expression in invasive breast carcinoma. Cancer Res 64: 7857-7866, 2004.
27. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332-7341, 2005.
28. Bono H and Okazaki Y: The study of metabolic pathways in tumors based on the transcriptome. Semin Cancer Biol 15: 290-299, 2005. (Pubitemid 41058774)
29. Adler AS, Lin M, Horlings H, Nuyten DSA, van de Vijver MJ and Chang HY: Genetic regulators of large-scale transcritptional signatures in cancer. Nat Genet 38: 421-430, 2006.
30. Rhodes DR and Chinnaiyan AM: Integrative analysis of the cancer transcriptome. Nat Genet 37: S31-S37, 2005.
31. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
32. Teicher BA, Ara G, Keyes SR, Herbst RS and Frei E III: Acute in vivo resistance in high-dose therapy. Clin Cancer Res 4: 483-491, 1998.
33. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B and Kinzler KW: Genes expressed in human tumor endothelium. Science 289: 1197-1202, 2000.
34. Bagley RG, Rouleau C, Morgenbesser SD, Weber W, Cook BP, Shankara S, Madden SL and Teicher BA: Pericytes from human non-small cell lung carcinomas: an attractive target for antiangiogenic therapy. Vasc Res 71: 163-174, 2006.
35. Nanda A and St. Croix B: Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16: 44-49, 2004.
36. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler K and St. Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61: 6649-6655, 2001.
37. Bagley R, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL and Teicher BA: Endothelial precursor cells as a model of tumor endothelium: characterization and comparison to mature endothelial cells. Cancer Res 63: 5866-5873, 2003. (Pubitemid 37187486)
38. Garmy-Susini B and Varner JA: Circulating endothelial progenitor cells. Br J Cancer 93: 855-858, 2005.
39. Modzelewski RA, Davies P, Watkins SC, Auerbach R, Chang M-J and Johnson CS: Isolation and identification of fresh tumorderived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54: 336-339, 1994.
40. Kaufman D, Hanson E, Lewis R, Auerbach R and Thomson J: Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 98: 10716-10721, 2001. (Pubitemid 32878687)
41. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner J: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997.
42. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M and Isner J: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228, 1999.
43. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M and Isner J: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999. (Pubitemid 29335849)
44. Lin Y, Weisdorf DJ, Solovey A and Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105: 71-77, 2000. (Pubitemid 30036389)
45. Rafii S: Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 105: 17-19, 2000.
46. + cells identifies a population of functional endothelial precursors. Blood 95: 952-958, 2000.
47. + endothelial precursor cells. Circ Res 88: 167-174, 2001.
48. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett N, Crystal R, Moore M, Hajjar K, Manova K, Benezra R and Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001.
49. + hematopoietic stem cells enhance tumor growth in a non-obese diabetic/severe combined immunodeficient mouse. Cancer Res 61: 7654-7659, 2001.
50. Auerbach R, Akhtar N, Lewis L and Shinners BL: Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 19: 167-172, 2000.
51. Bagley RG, Weber W, Rouleau C and Teicher BA: Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res 65: 9741-9750, 2005.
52. Baluk P, Hashizume H and McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111, 2005.
53. Von Tell D, Armulik A and Betsholtz C: Pericytes and vascular stability. Exp Cell Res 312: 623-629, 2006.
54. Armulik A, Abramsson A and Betsholtz C: Endothelial/pericyte interactions. Circ Res 97: 512-523, 2005.
55. Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, De Clerck YA and Marbaix E: Mechanisms of pericyte recruitment in tumor angiogenesis: a new role for metalloproteinases. Eur J Cancer 42: 310-318, 2006. (Pubitemid 43132885)
56. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K and Salven P: Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104: 2084-2086, 2004.
57. Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295, 2003.
58. Kemp KC, Hows J and Donaldson C: Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma 46: 1531-1544, 2005.
59. Martens TP, See F, Schuster MD, Sondermeijer HP, Hefti MM, Zannettino A, Gronthos S, Seki T and Itescu S: Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Prac 3 (Suppl 1): S18-S23, 2006.
60. Hung S-C, Deng W-P, Yang WK, Liu R-S, Lee C-C, Su T-C, Lin R-J, Yang D-M, Chang C-W, Chen W-H, Wei H-J and Gelovani JG: Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by non-invasive in vivo positron emission tomography imaging. Clin Cancer Res 11: 7749-7756, 2005.
61. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M and Lang FF: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005.
62. Hofmeister V, Vetter C, Schrama D, Brocker E-B and Becker JC: Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol Immunother 55: 481-494, 2006.
63. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA and Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
64. Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi H-P, Garin-Chesa P, Park JE, Rettig WJ and Lenter MC: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 276: 7408-7414, 2001. (Pubitemid 37392050)
65. Peerschke EIB and Gherbrehiwet B: Platelet C1Q receptor interactions with collagen and C1Q coated surfaces. J Immunol 145: 2984-2988, 1990.
66. Webster SD, Park M, Fonseca MI and Tenner AJ: Structural and functional evidence for microglial expression of C1qRp, the C1q receptor that enhances phagocytosis. J Leukoc Biol 67: 109-116, 2000. (Pubitemid 30046825)
67. Dean YD, McGreal EP, Akatsu H and Gasque P: Molecular and cellular properties of the rat AA4 antigen, a C-type lectin-like receptor with structural homology to thrombomodulin. J Biol Chem 275: 34382-34392, 2000.
68. Opavsky R, Haviernik P, Jurkovicova D, Garin MT, Copeland NG, Gilbert DJ, Jenkins NA, Bies J, Garfield S, Pastorekova S, Oue A and Wolff L: Molecular characterization of the mouse TEM 1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 276: 38795-38807, 2001.
69. Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St. Croix B, Kinzler KW and Huso DL: Tumor endothelial marker 1 (TEM1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA 103: 3351-3356, 2006.
70. Davies G, Cunnick GH, Mansel RE, Mason MD and Jiang WG: Levels of expression of endothelial markers specific to tumor-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis 21: 31-37, 2004.
71. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR and Dezube BJ: Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23: 982-989, 2005.
72. Wang H-W, Trotter MWB, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K and Boshoff C: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36: 687-693, 2004.
73. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D and Garin-Chesa P: Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immunity 5: 10-19, 2005.
74. Rupp C, Dolznig H, Puri C, Schweifer N, Sommergruber W, Kraut N, Rettig WJ, Kerjaschki D and Garin-Chesa P: Laser capture microdisection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn Mol Pathol 15: 35-42, 2006.
75. Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, Vernole P, Lacal PM and Graziani G: Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anti cancer drugs. Int J Oncol 27: 525-535, 2005.
76. Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schibert RD, Scharffetter-Kochanek K, Pehamberger H and Garin-Chesa P: Expression of stromal cell markers in distinct compartments of human skin. J Cutan Pathol 33: 145-155, 2006.
77. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG and Coukos G: Vascular leukocytes contribute to tumor vascularization. Blood 105: 679-681, 2005.
78. Brady J, Neal J, Sadakar N and Gasque P: Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol 63: 1274-1283, 2004.
79. MacFayden JR, Haworth O, Roberston D, Hardie D, Webster M-T, Morris HR, Panico M, Sutton-Smith M, Dell A, van der Greer P, Wienke D, Buckley CD and Isacke CM: Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumor endothelium. FEBS Lett 579: 2569-2575, 2005.
80. Marty C, Langer-Machova Z, Sigrist S, Schott, Schwendener RA and Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett 235: 1-11, 2006.
81. Zelensky AN and Gready JE: The C-type lectin-like domain superfamily. FEBS J 272: 6179-6217, 2005.
82. Zelensky AN and Gready JE: C-type lectin-like domains in Fugu rubripes. BMC Genom 5: 51-73, 2004.
83. Cambi A, Koopman M and Figdor CG: How C-type lectins detect pathogens. Cell Miobiol 7: 481-488, 2005.
84. Van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS and Geijtenbeek TBH: Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol 16: 488-493, 2004.
85. Vlachoyiannopoulos PG and Samarkos M: Peripheral vascular disease in antiphospholipid syndrome. Thrombosis Res 114: 509-519, 2004.
86. Van de Wouwer M, Collen D and Conway EM: Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 24: 1374-1383, 2004. (Pubitemid 39050428)
87. Hanly AM, Hayanga A, Winter DC and Bouchier-Hayes DJ: Thrombomodulin: tumor biology and prognostic implications. J Cancer Surg 31: 217-220, 2005. (Pubitemid 40361508)